Nils Bolstad

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 73 publications

Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab.

Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab.

Journal: BMJ neurology open
Published: December 01, 2025

Optimizing serum adalimumab levels in maintenance therapy via proactive therapeutic drug monitoring improves markers of disease activity in Crohn's disease.

Optimizing serum adalimumab levels in maintenance therapy via proactive therapeutic drug monitoring improves markers of disease activity in Crohn's disease.

Journal: Scandinavian journal of gastroenterology
Published: October 17, 2025

Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial.

Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial.

Journal: RMD open
Published: September 08, 2025

The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III Trial.

The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III Trial.

Journal: Therapeutic drug monitoring
Published: April 30, 2025

Fatigue in Inflammatory Bowel Disease: No Effect of Serum Concentrations of Infliximab, Adalimumab or Anti-Drug Antibodies During Maintenance Therapy.

Fatigue in Inflammatory Bowel Disease: No Effect of Serum Concentrations of Infliximab, Adalimumab or Anti-Drug Antibodies During Maintenance Therapy.

Journal: Scandinavian journal of immunology
Published: March 28, 2025

Tumour necrosis factor inhibitors in Ulcerative colitis: real-world data on Therapeutic drug monitoring and evaluation of current treatment targets (STRIDE II).

Tumour necrosis factor inhibitors in Ulcerative colitis: real-world data on Therapeutic drug monitoring and evaluation of current treatment targets (STRIDE II).

Journal: Annals of medicine
Published: January 06, 2025

Serological screening for coeliac disease in an adult general population: the HUNT study.

Serological screening for coeliac disease in an adult general population: the HUNT study.

Journal: Gut
Published: September 14, 2024

A simple automated assay format for measuring multiple immune checkpoint inhibitors.

A simple automated assay format for measuring multiple immune checkpoint inhibitors.

Journal: Journal of pharmaceutical and biomedical analysis
Published: August 27, 2024

Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial.

Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial.

Journal: RMD open
Published: August 16, 2024

Monoclonal Insulin Autoimmune Syndrome Successfully Treated With Plasma Cell Directed Therapy.

Monoclonal Insulin Autoimmune Syndrome Successfully Treated With Plasma Cell Directed Therapy.

Journal: Clinical lymphoma, myeloma & leukemia
Published: August 15, 2024

Efficacy of a Tumor Necrosis Factor Inhibitor in Chronic Low-Back Pain With Modic Type 1 Changes: A Randomized Controlled Trial.

Efficacy of a Tumor Necrosis Factor Inhibitor in Chronic Low-Back Pain With Modic Type 1 Changes: A Randomized Controlled Trial.

Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: August 07, 2024

Managing hemolysis in serum neuron-specific enolase measurements - an automated algorithm for routine practice.

Managing hemolysis in serum neuron-specific enolase measurements - an automated algorithm for routine practice.

Journal: Scandinavian journal of clinical and laboratory investigation
Published: June 10, 2024
Showing 1-12 of 73

Last Updated: 09/26/2026